NEWS

MultiplexDX NEWS

MultiplexDX Became a Proud Holder of the EIC Accelerator

MultiplexDX Receives Slovak Ministry of Health Grant

MultiplexDX moved their headquarters to Bratislava

MultiplexDX received the best SME instrument phase 2 evaluation score among Slovak companies

MultiplexDX expands their team

MultiplexDX Receives IPA4SME Grant

MultiplexDX officially presented as a new member of Oslo Cancer Cluster in June 2019

MultiplexDX joins the InvestHorizon Accelerator Programme

CEO of MultiplexDX in his fireside chat at Startup Grind Bratislava

CEO of MultiplexDX among speakers at 0100 Conference in Vienna

MultiplexDX among the nominees for Ernst & Young (EY) Entrepreneur of The Year 2018 Award

MultiplexDX hires new team members

Another Horizon 2020 Seal of Excellence for MultiplexDX from European Commission

CEO of MultiplexDX, Dr. Pavol Cekan, nominated for “Crystal Wing Awards”

MultiplexDX Becomes a Member of the Prestigious Oslo Cancer Cluster

Selected from the Best “Seal of Excellence” European Start-ups, MultiplexDX Gives a Pitch at Innovative Enterprise Vienna 2018

MultiplexDX Wins CESAwards’ "Best Social Impact Startup" in the CEE Region

MultiplexDX Applies for Patent to Secure its Revolutionary Technology

MultiplexDX Receives €1,2 Million in Investments

MultiplexDX Wins Three Central European Startup Awards

MultiplexDX Receives €176 000 Grant from the Slovak Ministry of Education

MultiplexDX Selected to Join Health Hub Vienna, One of Europe’s Premiere Accelerators

MultiplexDX Wins Standard of Excellence Awards from the Web Marketing Association (WMA)

MultiplexDX Was Awarded Horizon 2020 Seal of Excellence by the European Commission

MultiplexDX Wins Prestigious JCI Creative Young Entrepreneur Award 2018

MultiplexDX Is About to Close an Investment Round – Join Us

Multiplex DX Was Listed in the New Europe 100: Eastern Europe’s Emerging Technology Star

MultiplexDX Innovations. Unlocking the Full Potential of Personalized Cancer Diagnostics Through Multiplexed RNA-based Technologies.

MultiplexDX Launches FullRNALook - the Simplest and Most Robust RNA FISH on the Market

MultiplexDX Unveils Its Revolutionary Cancer Diagnostics Technology in a New Company Video

MultiplexDX Becomes an Overall Winner of the Prestigious Startup Awards 2016

PUBLICATIONS

Multiplexed miRNA Fluorescence In Situ Hybridization for Formalin-Fixed Paraffin-Embedded Tissues

Methods in Molecular Biology

Multicolor microRNA FISH effectively differentiates tumor types

The Journal of Clinical Investigation

Identification of Single-Base Mismatches in Duplex DNA by EPR Spectroscopy

Journal of the American Chemical Society

Folding of the cocaine aptamer studied by EPR and fluorescence spectroscopies using the bifunctional spectroscopic probe C

Nucleic Acids Research

Relative Orientation of Rigid Nitroxides by PELDOR: Beyond Distance Measurements in Nucleic Acids

Angewandte Chemie International Edition

Rigid spin-labeled nucleoside C¸ : a nonperturbing EPR probe of nucleic acid conformation

Nucleic Acids Research

Single base interrogation by a fluorescent nucleotide: each of the four DNA bases identified by fluorescence spectroscopy

Chemical Communications

Inside Cover

Angewandte Chemie International Edition

PRESS ABOUT MultiplexDX

Rozhovor s biotechnológom Palom Čekanom

MultiplexDX on Track to Launch New FISH, NGS-Based Breast Cancer Test by 2023

Rakovina má čiarový kód

Pavol Čekan: Ak mám tvoriť úspešný príbeh, tak na Slovensku

Biochemik Pavol Čekan: Slováci spresnia liečbu rakoviny

Vedec Čekan: Máme v rukách revolučnú technológiu, pomôže množstvu pacientov

Nová investícia do diagnostiky rakoviny. MultiplexDX získal 2,5 milióna eur

Zázraky na poli medicíny

Posun v liečbe rakoviny je neuveriteľný, stále je čo doháňať

Personalizovaná medicína v diagnostike rakoviny

Primárnou motiváciou je pacient

MultiplexDX — Best Social Impact Startup CESAwards 2018

MultiplexDX to End Cancer Misdiagnosis. How?

Miliónová investícia do diagnostiky rakoviny. Slovenský MultiplexDX dostal injekciu

Polovica pacientov dostáva podľa vedca chemoterapiu zbytočne. Vyvíjajú test, ktorý má odstrániť chyby pri diagnostike

Ocenili mladých podnikateľov. Ich nápady prerazili i za hranicami

Pavol Čekan vyvíja špičkový test na liečbu rakoviny. Blíži sa na trh

Personalizovaná diagnostika nesmie byť iba nejakým „ROLLS-ROYCEOM“

Portrét Pavla Čekana

Diagnostic tests that lead to personalized treatment

Slovák, ktorý patrí k svetovej špičke. Vyvíja unikátne metódy na boj s rakovinou

Startup MultiplexDX vyvíja diagnostické testy na liečbu nádorov

Biochemik Pavol Čekan: “Najväčší úspech slovenskej vedy je, že ešte stále tu je.”

Unlocking the Full Potential of Personalized Medicine through Multiplexed RNA-Based Technologies

Liečme lepšie rakovinu

Startup Awards 2016 Winners

Lighting up micro RNAs

See all MultiplexDX clients